Lung Cancer Rx podcast

More Accuracy, Less Speed? ASCO 2026 Data Further Support Targeted Therapy in Early-Stage NSCLC

0:00
24:27
Rewind 15 seconds
Fast Forward 15 seconds

Data presented at ASCO 2026 further underscore the importance of identifying which patients with early-stage NSCLC are eligible for targeted therapies. Jamie E. Chaft, MD, discusses results from the LIBRETTO, CROWN, and EA5142 trials with LungCancerRx hosts Aakash Desai, MD, MPH, Eric K. Singhi, MD, and Fawzi F. Abu Rous, MD.

More episodes from "Lung Cancer Rx"